Evidence map›Paper›PMID 35034346›Full record

ArticlePharmacoEconomics - open2022

Prevalence and Cost of Care for Parkinson's Disease in Luxembourg: An Analysis of National Healthcare Insurance Data.

Susanne Schmitz, Michel Vaillant, Christell Renoux, Robert L Konsbruck, Pierre Hertz, Magali Perquin, Lukas Pavelka, Rejko Krüger, Laetitia Huiart

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PharmacoEconomics - open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Susanne SchmitzCompetence Center for Methodology and Statistics, Department of Population Health, Luxembourg Institute of Health, 1a-b Rue Thomas Edison, 1445, Strassen, Luxembourg. SusanneSchmitz779@gmail.com.ORCID http://orcid.org/0000-0003-4753-1709
Michel VaillantCompetence Center for Methodology and Statistics, Department of Population Health, Luxembourg Institute of Health, 1a-b Rue Thomas Edison, 1445, Strassen, Luxembourg.
Christell RenouxCentre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Robert L KonsbruckCaisse Nationale de Santé, Luxembourg, Luxembourg.
Pierre HertzCaisse Nationale de Santé, Luxembourg, Luxembourg.
Magali PerquinDepartment of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg.
Lukas PavelkaClinical and Experimental Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Rejko KrügerParkinson's Research Clinic, Centre Hospitalier de Luxembourg (CHL), Luxembourg, Luxembourg.
Laetitia HuiartDepartment of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg.

Funding

Fonds National de la Recherche Luxembourg FNR/P13/6682797
6 · The paper itself

Abstract

backgroundParkinson's disease (PD) is the second most common neurodegenerative disorder, with an increasing prevalence worldwide. Estimates of the economic burden associated with PD vary widely across existing studies due to differences in setting and study design. The prevalence and cost of care for PD in Luxembourg are currently unknown.

objectiveThe aims of this study were to estimate (1) the prevalence of PD in Luxembourg and (2) the cost of care for PD to the national healthcare insurance based on routinely collected healthcare data.

methodsThis analysis was based on individual patient-level data collected by the national healthcare insurance in Luxembourg during 2007-2017, which covers over 95% of the resident population. People with PD were identified based on drug reimbursement profiles. Cost of care was estimated according to a comparative analysis of the healthcare resources consumed by people with PD compared with an age- and sex-matched control group.

resultsWe determined a PD prevalence of 928 per 100,000 individuals aged 50 years and older in 2016, higher in men (1032 per 100,000) than in women (831 per 100,000). The total mean cost of care for PD was estimated at €22,673 per patient per year in 2016, with the highest costs being associated with long-term care (69%).

conclusionThis was the first attempt to estimate the prevalence and cost of care of PD in Luxembourg. The work demonstrated the usefulness of routinely collected data in Luxembourg for such analyses. Our study confirms the significant burden of PD to the healthcare system, especially on long-term care.

Identifiers

PMID35034346
PMCPMC8761379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.